ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,555,562 | -21.9% | 610,006 | -11.6% | 0.00% | -33.3% |
| Q2 2023 | $21,209,001 | -17.5% | 689,948 | -3.3% | 0.01% | -14.3% |
| Q1 2023 | $25,695,407 | -77.4% | 713,167 | -75.3% | 0.01% | -78.8% |
| Q4 2022 | $113,935,764 | -9.4% | 2,882,990 | -7.9% | 0.03% | -17.5% |
| Q3 2022 | $125,796,000 | +12.9% | 3,130,851 | +18.1% | 0.04% | +17.6% |
| Q2 2022 | $111,469,000 | +318.7% | 2,651,493 | +288.0% | 0.03% | +385.7% |
| Q1 2022 | $26,623,000 | +22.9% | 683,367 | +25.7% | 0.01% | +40.0% |
| Q4 2021 | $21,663,000 | -4.6% | 543,599 | -13.5% | 0.01% | -16.7% |
| Q3 2021 | $22,704,000 | -20.1% | 628,210 | -9.4% | 0.01% | -14.3% |
| Q2 2021 | $28,427,000 | -1.7% | 693,518 | +4.7% | 0.01% | -12.5% |
| Q1 2021 | $28,904,000 | +174.0% | 662,633 | +214.4% | 0.01% | +166.7% |
| Q4 2020 | $10,548,000 | -69.9% | 210,735 | -74.7% | 0.00% | -75.0% |
| Q3 2020 | $35,008,000 | -3.9% | 832,121 | +10.9% | 0.01% | -7.7% |
| Q2 2020 | $36,413,000 | – | 750,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |